LAUSR

Conventional treatment for neurotrophic keratopathy is mainly palliative and aims at promoting corneal epithelial regrowth. Medical management is prescribed in the early stages and comprises preservative‐free lubricants, topical antibiotics, and blood‐derived eye drops, whereas surgical interventions such as tarsorrhaphy, amniotic membrane transplantation, and tectonic keratoplasty are reserved for the more severe cases.[1] Recently, topical recombinant human nerve growth factor (rhNGF) has been approved by the United States Food and Drug Administration (FDA) as a treatment for neurotrophic keratopathy. rhNGF directly targets the underlying deficits of neurotrophic keratopathy; however, it does not restore corneal sensitivity and its cost remains prohibitive to patients.[2]